Abstract
Viral infections are some of the most frequent complications in patients with hematologic malignancies are viral infections. Infections caused by cytomegalovirus, herpes simplex virus, varicella zoster virus, hepatitis B virus and influenza virus are associated with high morbidity and mortality in this vulnerable population. Fortunately, a growing number of antiviral medications and vaccines are allowing for more effective prophylaxis against these pathogens. This article reviews the epidemiology and prophylactic strategies available for these opportunistic viral pathogens.
Keywords: Cytomegalovirus, herpes simplex virus, varicella zoster virus, influenza virus, hepatitis B virus, hematologic malignancy, anti-viral agents, vaccines, prophylaxis, T-cell dysfunction, lymphoid derived leukemia, mye-loid derived leukemia, chronic lymphocytic leukemia, fludarabine, monoclonal antibodies, pneumonitis, alemtuzumab, oral acyclovir
Infectious Disorders - Drug Targets
Title: Epidemiology and Prevention of Viral Infections in Patients with Hematologic Malignancies
Volume: 11 Issue: 1
Author(s): Michael Angarone
Affiliation:
Keywords: Cytomegalovirus, herpes simplex virus, varicella zoster virus, influenza virus, hepatitis B virus, hematologic malignancy, anti-viral agents, vaccines, prophylaxis, T-cell dysfunction, lymphoid derived leukemia, mye-loid derived leukemia, chronic lymphocytic leukemia, fludarabine, monoclonal antibodies, pneumonitis, alemtuzumab, oral acyclovir
Abstract: Viral infections are some of the most frequent complications in patients with hematologic malignancies are viral infections. Infections caused by cytomegalovirus, herpes simplex virus, varicella zoster virus, hepatitis B virus and influenza virus are associated with high morbidity and mortality in this vulnerable population. Fortunately, a growing number of antiviral medications and vaccines are allowing for more effective prophylaxis against these pathogens. This article reviews the epidemiology and prophylactic strategies available for these opportunistic viral pathogens.
Export Options
About this article
Cite this article as:
Angarone Michael, Epidemiology and Prevention of Viral Infections in Patients with Hematologic Malignancies, Infectious Disorders - Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/187152611794407773
DOI https://dx.doi.org/10.2174/187152611794407773 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
B Cells and Beyond: Therapeutic Opportunities Targeting Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) P38 MAPK Contributes to Resistance and Invasiveness of HER2- Overexpressing Breast Cancer
Current Medicinal Chemistry Antifungal Therapy of Aspergillosis of the Central Nervous System and Aspergillus Endophthalmitis
Current Pharmaceutical Design Ginkgolic Acids Confer Potential Anticancer Effects by Targeting Pro- Inflammatory and Oncogenic Signaling Molecules
Current Molecular Pharmacology Could Resveratrol be a Useful Drug for the Treatment of Malignant Hemopathies?
Recent Patents on Anti-Cancer Drug Discovery PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets Primary Sjogren’s Syndrome and the Type I Interferon System
Current Pharmaceutical Biotechnology Molecular Targets and Targeted Therapies for Malignant Mesothelioma
Current Medicinal Chemistry HLA-G - From Fetal Tolerance to a Regulatory Molecule in Inflammatory Diseases
Current Immunology Reviews (Discontinued) Prostate Cancer Horizons in the Development of Novel Anti-Cancer Strategies
Current Medicinal Chemistry - Anti-Cancer Agents Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry The Insulin-Like Growth Factor (IGF) Signaling Pathway: Strategies for Successful Therapeutic Tasks in Cancer Treatment
Current Cancer Therapy Reviews Chemotherapy and Delivery in the Treatment of Primary Brain Tumors
Current Clinical Pharmacology Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry Radiopharmaceuticals Labelled with Copper Radionuclides: Clinical Results in Human Beings
Current Radiopharmaceuticals Predictive Factors of Febrile Neutropenia Induced by Anticancer Chemotherapy in the South of Tunisia
Reviews on Recent Clinical Trials Nanoparticles for Cancer Targeting: Current and Future Directions
Current Drug Delivery Implications of Somatic Mutations in the AML1/RUNX1 Gene in Myelodysplastic Syndrome (MDS): Future Molecular Therapeutic Directions for MDS
Current Cancer Drug Targets New Perspectives of HIV/AIDS Therapy Study
Recent Patents on Anti-Infective Drug Discovery Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design